Myrthe Rouwette

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

Miranda M.C. van der Lee, Patrick G. Groothuis, Ruud Ubink et al. · Molecular Cancer Therapeutics · 2015 · 215 citations

Pharmacy, Oncology, Pharmacology +16

Unraveling the Interaction between Carboxylesterase 1c and the Antibody–Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice

Ruud Ubink, Eef H.C. Dirksen, Myrthe Rouwette et al. · Molecular Cancer Therapeutics · 2018 · 50 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Progressive Sensorineural Hearing Loss and Normal Vestibular Function in a Dutch DFNB7/11 Family with a Novel Mutation in <i>TMC1</i>

Anne-Martine R. de Heer, Rob W.J. Collin, P.L.M. Huygen et al. · Audiology and Neurotology · 2010 · 40 citations

Medicine, Genetics, Molecular Genetics +15

Sperm-Associated Antigen 16 Is a Novel Target of the Humoral Autoimmune Response in Multiple Sclerosis

Laura Bock, Klaartje Somers, Judith Fraussen et al. · The Journal of Immunology · 2014 · 26 citations · Full text

Life Sciences, Immunology, Neurology +17

Identification of coronin‐1a as a novel antibody target for clinically isolated syndrome and multiple sclerosis

Myrthe Rouwette, Jean‐Paul Noben, Jack van Horssen et al. · Journal of Neurochemistry · 2013 · 19 citations · Full text

Pharmacy, Neurology, Neuroscience +17